In HNSCC it has been previously found that HER2 is co-expressed with HER1 [36], and this co-expression may contribute to the negative prognostic impact of HER1, being associated with resistance to therapeutic agents [37, 38]. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.